Laboratory Assessment Options

Comprehensive Metabolic Panel/Chemistry Panel
The CMP is a screening tool used to evaluate organ function and check for conditions such as kidney or liver disease and diabetes. Blood glucose and electrolytes are evaluated as they can be influenced by a variety of acute and chronic illnesses. Protein evaluation reflects liver function. Iron studies evaluate for deficiency states which could result in anemia.
 
Complete Blood Count
The CBC is screening test that is used to check for disorders such as anemia, cancer, infection and inflammation among others. This blood tests looks at types and levels of white blood cells and red blood cells along with oxygen-carrying proteins in the blood. Platelet count analysis can point to conditions that could result in bleeding or clotting disorders. Vitamin and iron deficiencies may also be identified.
 
Urinalysis
This screening test can provide a general overview of a person's health or specific disease states. Performed on a urine sample, this assessment may detect multiple metabolic and kidney disorders including urinary tract infections, diabetes and cancers.
 
Hgb A1c
Chronically elevated glucose levels may cause damage to body organs such as the eyes, heart, blood vessels, kidneys and nerves. The A1c test monitors glucose control over the last several months. Elevations may reflect the presence of diabetes mellitus or pre-diabetic states where increased risk for developing diabetes may be identified.
 
TSH/Free Thyroxin Index (T uptake, Thyroxin T4, T7)
These tests are used to screen for thyroid function and disorders such as hyper or hypothyroidism and may reflect acute or chronic dysfunction. Abnormal levels may also indicate a problem with the pituitary gland or side effects of certain medications.
 
PSA for men
Prostate-specific antigen (PSA) is a protein produced by the prostate gland which can be measured in the blood and used to detect disease. This test is used in combination with the digital rectal exam to help detect prostate cancer in men 50 years of age or older or at age 40 or 45 in men who are at a higher risk for prostate cancer like those with a family history of prostate cancer or African Americans.
In order to provide results during the day of your assessment, our phlebotomist will visit your home or office at least two weeks prior to your Executive Assessment to draw your blood.